InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: dcaf7 post# 238

Wednesday, 02/15/2023 8:03:07 AM

Wednesday, February 15, 2023 8:03:07 AM

Post# of 575
APTO has several potential short term financing options to get to real PPS moving data.

1. Outl-icensing of Lux for non-cancer indications.
2. Partnering of Lux for NHL indications.
2. Non-dilutive milestone driven loan tranches.
3. Possible Hanmi equity investment as they did to help SPPI.
4. Near term (positive surprise data); I believe that the initial combo data will be such.

Currently we have an ORR for r/rAmL in the range of 20% with TUSP monotherapy. I believe that the ORR for r/rAML will be in the 40%+ range with TUSP + Venetoclax. That will be a positive surprise and I expect such data around the third quarter.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News